about
Medical and alternative therapies in urinary tract stone diseaseNutritional Management of Kidney Stones (Nephrolithiasis)Medical treatment of pediatric urolithiasisOxalate-degrading activity in Bifidobacterium animalis subsp. lactis: impact of acidic conditions on the transcriptional levels of the oxalyl coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes.Dietary hyperoxaluria is not reduced by treatment with lactic acid bacteria.Nephrolithiasis after bariatric surgery for obesity.Kidney stone risk following modern bariatric surgery.DETECTION OF LACTOBACILLI IN MONTHLY MAIL-IN STOOL SAMPLES FROM 3-18 MONTHS OLD INFANTS AT GENETIC RISK FOR TYPE 1 DIABETES.The metabolic and ecological interactions of oxalate-degrading bacteria in the Mammalian gut.Nutritional aspect of nephrolithiasisThe colon: an overlooked site for therapeutics in dialysis patients.Factors related to colonization with Oxalobacter formigenes in U.S. adults.Pharmacotherapy of urolithiasis: evidence from clinical trials.Probiotics and other key determinants of dietary oxalate absorptionPediatric primary urolithiasis: Symptoms, medical management and prevention strategies.Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluriaHyperoxaluria and systemic oxalosis: current therapy and future directions.Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones.The roles and mechanisms of intestinal oxalate transport in oxalate homeostasis.Kidney stones: an update on current pharmacological management and future directions.Prevention and treatment of urinary tract infection with probiotics: Review and research perspectiveConstruction of vectors for inducible and constitutive gene expression in LactobacillusDiet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.Gut microbiota and oxalate homeostasis.Probiotics for prevention of urinary stones.Malabsorption syndrome as a rare cause of nephrocalcinosis.Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.Update on oxalate crystal disease.Kidney stone incidence and metabolic urinary changes after modern bariatric surgery: review of clinical studies, experimental models, and prevention strategies.Kidney stone risk following Roux-en-Y gastric bypass surgery.Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1.Enteric hyperoxaluria: an important cause of end-stage kidney disease.The intestine and the kidneys: a bad marriage can be hazardous.Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria.Stone formation and management after bariatric surgery.Moderately increased risk of urinary stone disease in patients with biopsy-verified coeliac disease.The management of patients with enteric hyperoxaluria.The gut-kidney axis in chronic renal failure: A new potential target for therapy.[Microbiota and probiotics: effects on human health].Genomic analysis by deep sequencing of the probiotic Lactobacillus brevis KB290 harboring nine plasmids reveals genomic stability.
P2860
Q26777616-D5A3E94B-B60E-40A2-BC93-636A5034C022Q26801209-AAFF9C4F-6B21-4766-BC18-168F9B55DDAAQ28751145-9372A15B-D300-4EB2-91F7-0F4DE00EF6ACQ33624952-30E3CA54-D554-4A2B-B096-B80294D54FB2Q33645350-256C63C7-5971-4161-BB9A-84E1DD208897Q33700670-366F7582-08E3-4F90-BC90-0DB376050988Q33759672-48D2A6C8-0CEE-415D-8734-52B7FC63D0FBQ33911583-2CA9FA71-DD7F-464B-BB93-F4F32EBC8C58Q34533525-2F3E416E-FE0C-4C40-9EB5-DB5E1DEA890FQ34553719-3AABF9B2-E25F-47C4-B8CA-A0BF73DBB51CQ34607428-0A8C9377-3542-48E2-8F0F-73769EB47BC7Q34766036-A257BC5A-0F05-4878-9EAE-65A077E41570Q34936200-59B2FD58-2FFE-462A-9052-CE988EA7845DQ34955083-16569C44-5F19-4349-BCFA-FCC4450ACE00Q36033738-B2DFDE05-DC25-4FA4-9D22-B60D2D978065Q36239614-FD074FCD-17DB-420A-8BBA-9C595AB480F0Q36613873-EC5477A3-EB0A-4AB4-984A-DD3845F7F713Q36677659-68B21972-6DDC-42DB-BD8E-2E9F681C99B0Q37116388-FDB00B60-3014-4124-A766-0B37DF70A531Q37169623-63B1B9E7-B240-4572-9181-CF312A67F10EQ37197599-E5B95C70-9772-4B82-B7DE-E55CEB510FBCQ37283892-57015270-13A7-4260-8940-821489203EEBQ37582208-F5C55988-BCE4-45F5-8A11-E52DBAEBC304Q37634448-AC604ACE-14D4-4239-9CE2-598D28A64796Q37634461-006C8B56-99B1-4B88-B271-CB297F48D38BQ37653291-526C0865-DEBC-4F09-ADFA-F7F11FD59511Q38098897-FD392014-DC60-429A-BB02-6128EAE2BA7AQ38105961-F2866A25-656C-479F-A68A-69003FE9D595Q38223535-687A4A82-C04B-4AD9-98C4-44FDA077C44AQ38282915-1641E902-0659-447C-A2F4-D9BCC99C81DEQ38302375-494DECFC-EA04-40CA-8BAC-5AB99633A01CQ38363406-359223F8-E520-4CAB-9CB0-43AE176D7D93Q38393212-E0B57819-F700-4296-8525-C8234A62234EQ38404011-1A60195F-E369-4878-B3B2-A61A27F7A2FBQ38409982-837427E6-E159-473C-9BEC-08DD54B264C5Q38435129-294E9183-F868-4805-A4FA-1590858FCEEEQ38662272-50DE8D70-62A2-42B3-8B85-C93E7415BF10Q38955879-625C9CF0-E985-4D99-BB23-676581F52A3EQ39281119-3914236F-ADE9-4621-8630-695DF7CE4839Q39356909-FA3AB9CC-2D56-4D39-8F40-44628321FE39
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Use of a probiotic to decrease enteric hyperoxaluria.
@ast
Use of a probiotic to decrease enteric hyperoxaluria.
@en
type
label
Use of a probiotic to decrease enteric hyperoxaluria.
@ast
Use of a probiotic to decrease enteric hyperoxaluria.
@en
prefLabel
Use of a probiotic to decrease enteric hyperoxaluria.
@ast
Use of a probiotic to decrease enteric hyperoxaluria.
@en
P2093
P1433
P1476
Use of a probiotic to decrease enteric hyperoxaluria.
@en
P2093
Claudio De Simone
Cynthia Regnier
John C Lieske
P304
P356
10.1111/J.1523-1755.2005.00520.X
P407
P577
2005-09-01T00:00:00Z
P5875
P6179
1030947012